Rani Therapeutics, Celltrion Expand Partnership To Include Adalimumab Biosimilar For RT-105
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics (NASDAQ:RANI) has expanded its partnership with Celltrion to develop RT-105, an orally administered adalimumab biosimilar. This follows their initial collaboration for the development of RT-111, an orally administered ustekinumab biosimilar, announced in January.

June 05, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics expands its partnership with Celltrion to develop RT-105, an orally administered adalimumab biosimilar, potentially boosting Rani's product pipeline.
The expanded partnership with Celltrion for the development of RT-105, an adalimumab biosimilar, strengthens Rani Therapeutics' product pipeline and could lead to increased investor interest. This collaboration follows their initial partnership for RT-111, an ustekinumab biosimilar, announced earlier this year. The news is directly related to Rani Therapeutics and is likely to have a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100